Experienced in Prolactinoma

Dr. Timothy J. Harris

Radiation Oncology
Mcv Associated Physicians
9000 Stony Point Pkwy, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Prolactinoma
Mcv Associated Physicians
9000 Stony Point Pkwy, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Harris is a Radiation Oncologist in Richmond, Virginia. Dr. Harris and is rated as an Experienced provider by MediFind in the treatment of Prolactinoma. His top areas of expertise are Posterior Fossa Tumor, Meningioma, Metastatic Brain Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Harris is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in VA
Hospital Affiliations
Medical College Of Virginia Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS

Locations

MCV ASSOCIATED PHYSICIANS
9000 Stony Point Pkwy, Richmond, VA 23235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: March 07, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Atezolizumab, Tocilizumab
Study Phase: Phase 2
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Radiation, Drug
Study Drug: Lapatinib Ditosylate
Study Phase: Phase 2
View 8 Less Clinical Trials

13 Total Publications

Mathematical modeling of meningioma volume change after radiation treatment.
Mathematical modeling of meningioma volume change after radiation treatment.
Journal: Clinical neurology and neurosurgery
Published: May 22, 2024
Similar Doctors
Distinguished in Prolactinoma
Dr. James M. Larner
Radiation Oncology | Radiology
Distinguished in Prolactinoma
Dr. James M. Larner
Radiation Oncology | Radiology

University Of Virginia Physicians Group

1 Hospital Dr, Fl 3, 
Charlottesville, VA 
 (60.9 mi)
434-924-1984
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Larner is a Radiation Oncologist and a Radiologist in Charlottesville, Virginia. Dr. Larner and is rated as a Distinguished provider by MediFind in the treatment of Prolactinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Posterior Fossa Tumor, Thalamotomy, and Gamma Knife Radiosurgery. Dr. Larner is currently accepting new patients.

Advanced in Prolactinoma
Dr. David M. Randolph
Radiation Oncology
Advanced in Prolactinoma
Dr. David M. Randolph
Radiation Oncology

Virginia Radiation Oncology Associates Inc

1401 Johnston Willis Dr, 
North Chesterfield, VA 
 (3.3 mi)
804-483-5164
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Randolph is a Radiation Oncologist in North Chesterfield, Virginia. Dr. Randolph and is rated as a Distinguished provider by MediFind in the treatment of Prolactinoma. His top areas of expertise are Posterior Fossa Tumor, Lung Cancer, Pleuropulmonary Blastoma, and Trigeminal Neuralgia. Dr. Randolph is currently accepting new patients.

Experienced in Prolactinoma
Dr. David M. Randolph
Radiation Oncology
Experienced in Prolactinoma
Dr. David M. Randolph
Radiation Oncology

Virginia Radiation Oncology Associates Inc

1401 Johnston Willis Dr, 
North Chesterfield, VA 
 (3.3 mi)
804-483-5164
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Randolph is a Radiation Oncologist in North Chesterfield, Virginia. Dr. Randolph and is rated as a Distinguished provider by MediFind in the treatment of Prolactinoma. His top areas of expertise are Posterior Fossa Tumor, Pleuropulmonary Blastoma, Lung Cancer, Gamma Knife Radiosurgery, and Advanced Bronchoscopy. Dr. Randolph is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harris's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 20 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile